Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Virol ; 85(19): 9801-10, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21752900

ABSTRACT

Epstein-Barr virus (EBV) transforms B lymphocytes through the expression of the latent viral proteins EBNA and latent membrane protein (LMP). Recently, it has become apparent that microRNAs (miRNAs) also contribute to EBV's oncogenic properties; recombinant EBVs that lack the BHRF1 miRNA cluster display a reduced ability to transform B lymphocytes in vitro. Furthermore, infected cells evince a marked upregulation of the EBNA genes. Using recombinant viruses that lack only one member of the cluster, we now show that all three BHRF1 miRNAs contribute to B-cell transformation. Recombinants that lacked miR-BHRF1-2 or miR-BHRF1-3 displayed enhanced EBNA expression initiated at the Cp and Wp promoters. Interestingly, we find that the deletion of miR-BHRF1-2 reduced the expression level of miR-BHRF1-3 and possibly that of miR-BHRF1-1, demonstrating that the expression of one miRNA can potentiate the expression of other miRNAs located in the same cluster. Therefore, the phenotypic traits of the miR-BHRF1-2 null mutant could result partly from reduced miR-BHRF1-1 and miR-BHRF1-3 expression levels. Nevertheless, using an miR-BHRF1-1 and miR-BHRF1-3 double mutant, we could directly assess and confirm the contribution of miR-BHRF1-2 to B-cell transformation. Furthermore, we found that the potentiating effect of miR-BHRF1-2 on miR-BHRF1-3 synthesis can be reproduced with simple expression plasmids, provided that both miRNAs are processed from the same transcript. Therefore, this enhancing effect does not result from an idiosyncrasy of the EBV genome but rather reflects a general property of these miRNAs. This study highlights the advantages of arranging the BHRF1 miRNAs in clusters: it allows the synchronous and synergistic expression of genetic elements that cooperate to transform their target cells.


Subject(s)
B-Lymphocytes/virology , Cell Transformation, Viral , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/pathogenicity , MicroRNAs/metabolism , RNA, Viral/metabolism , Virulence Factors , Cell Line , Gene Expression Regulation, Viral , Humans , MicroRNAs/genetics , RNA, Viral/genetics , Viral Proteins/biosynthesis
2.
PLoS Pathog ; 7(2): e1001294, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21379335

ABSTRACT

Epstein-Barr virus (EBV), an oncogenic human herpesvirus, induces cell proliferation after infection of resting B lymphocytes, its reservoir in vivo. The viral latent proteins are necessary for permanent B cell growth, but it is unknown whether they are sufficient. EBV was recently found to encode microRNAs (miRNAs) that are expressed in infected B cells and in some EBV-associated lymphomas. EBV miRNAs are grouped into two clusters located either adjacent to the BHRF1 gene or in introns contained within the viral BART transcripts. To understand the role of the BHRF1 miRNA cluster, we have constructed a virus mutant that lacks all its three members (Δ123) and a revertant virus. Here we show that the B cell transforming capacity of the Δ123 EBV mutant is reduced by more than 20-fold, relative to wild type or revertant viruses. B cells exposed to the knock-out virus displayed slower growth, and exhibited a two-fold reduction in the percentage of cells entering the cell cycle S phase. Furthermore, they displayed higher latent gene expression levels and latent protein production than their wild type counterparts. Therefore, the BHRF1 miRNAs accelerate B cell expansion at lower latent gene expression levels. Thus, this miRNA cluster simultaneously enhances expansion of the virus reservoir and reduces the viral antigenic load, two features that have the potential to facilitate persistence of the virus in the infected host. Thus, the EBV BHRF1 miRNAs may represent new therapeutic targets for the treatment of some EBV-associated lymphomas.


Subject(s)
Cell Transformation, Viral , Epstein-Barr Virus Infections/genetics , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/pathogenicity , MicroRNAs/genetics , Viral Proteins/genetics , B-Lymphocytes/virology , Blotting, Western , Cell Cycle , Cells, Cultured , Epstein-Barr Virus Infections/virology , Humans , Kidney/cytology , Kidney/metabolism , Kidney/virology , Lung/embryology , Lung/metabolism , Lung/virology , Lymphoma/genetics , Lymphoma/virology , MicroRNAs/metabolism , Mutation/genetics , RNA, Messenger/genetics , RNA, Viral/genetics , RNA, Viral/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Transcription, Genetic , Viral Proteins/metabolism , Virus Latency , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL
...